Luyan Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Cash & Equivalents	555.93	616.96	576.85	606.3	594.19	415.43
Cash & Short-Term Investments	555.93	616.96	576.85	606.3	594.19	415.43
Cash Growth	21.41%	6.95%	-4.86%	2.04%	43.03%	-30.40%
Accounts Receivable	6,540	6,392	5,951	5,673	5,849	5,101
Other Receivables	109.16	103.42	108.33	94.59	87.49	117.17
Receivables	6,649	6,495	6,059	5,768	5,937	5,218
Inventory	2,851	3,035	2,865	2,574	2,549	2,275
Prepaid Expenses	-	0.02	0.02	0.25	0.33	0.08
Other Current Assets	360.54	310.48	369.1	370.33	668.17	414.12
Total Current Assets	10,416	10,458	9,870	9,319	9,748	8,322
Property, Plant & Equipment	2,091	2,099	1,928	1,653	1,425	1,037
Long-Term Investments	62.32	63.84	53.41	48.85	34.21	31.3
Goodwill	289.28	289.28	289.28	288.65	289.45	289.45
Other Intangible Assets	353.86	356.38	361.09	355.16	176.93	167.81
Long-Term Deferred Tax Assets	79.56	78.45	75.79	66.37	54.71	43.39
Long-Term Deferred Charges	23.84	24.26	29.04	28.58	28.96	32.82
Other Long-Term Assets	24.92	26.54	31.5	34.46	26.08	68.98
Total Assets	13,341	13,396	12,639	11,794	11,784	9,993
Accounts Payable	4,283	4,710	4,004	3,444	3,258	2,410
Accrued Expenses	41.4	94.08	86.74	98.53	119.54	111.6
Short-Term Debt	4,448	4,088	3,875	3,990	4,455	4,130
Current Portion of Long-Term Debt	325.68	340.55	293.91	171.26	58.25	47.31
Current Portion of Leases	-	52.26	46.67	43.54	37.98	41.69
Current Income Taxes Payable	50.22	34.48	36.67	43.98	43.47	45.42
Current Unearned Revenue	15.94	19.27	30.72	22.38	31.78	10.57
Other Current Liabilities	247.84	243.19	232.47	211.84	296.53	217.69
Total Current Liabilities	9,411	9,582	8,605	8,026	8,301	7,015
Long-Term Debt	382.86	327.23	648.41	578.63	475.04	226.6
Long-Term Leases	81.03	81.64	87.33	74.33	53.86	40.37
Long-Term Unearned Revenue	38.2	38.24	38.83	39.76	41.2	41.85
Long-Term Deferred Tax Liabilities	6.2	6.27	6.54	6.81	7.07	7.34
Other Long-Term Liabilities	31.69	35.92	60.14	90.98	114.97	101.17
Total Liabilities	9,951	10,072	9,447	8,817	8,993	7,433
Common Stock	388.52	388.52	388.52	388.52	388.52	388.52
Additional Paid-In Capital	617.81	617.81	617.54	631.05	653.6	656.37
Retained Earnings	2,365	2,297	2,152	1,923	1,676	1,447
Comprehensive Income & Other	3.4	3.82	4.24	3.84	2.82	-0.5
Total Common Equity	3,374	3,307	3,162	2,946	2,721	2,492
Minority Interest	15.2	17.09	29.67	30.68	69.84	68.47
Shareholders' Equity	3,390	3,324	3,192	2,977	2,791	2,560
Total Liabilities & Equity	13,341	13,396	12,639	11,794	11,784	9,993
Total Debt	5,237	4,890	4,951	4,858	5,080	4,486
Net Cash (Debt)	-4,681	-4,273	-4,374	-4,252	-4,486	-4,071
Net Cash Per Share	-11.97	-10.95	-11.26	-10.99	-11.57	-10.51
Filing Date Shares Outstanding	388.52	388.52	388.52	388.52	388.52	388.52
Total Common Shares Outstanding	388.52	388.52	388.52	388.52	388.52	388.52
Working Capital	1,005	875.26	1,265	1,292	1,447	1,307
Book Value Per Share	8.69	8.51	8.14	7.58	7.00	6.41
Tangible Book Value	2,731	2,661	2,512	2,302	2,254	2,034
Tangible Book Value Per Share	7.03	6.85	6.47	5.93	5.80	5.24
Buildings	-	1,800	1,443	1,001	899.38	858.76
Machinery	-	303.7	278.43	259.22	214.51	196.8
Construction In Progress	-	320.85	471.48	616.59	509.06	139.74

Source: S&P Global Market Intelligence. Standard template. Financial Sources.